MedTrace Logo

Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy

NCT00116714 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4968

Last updated 2011-05-06

No results posted yet for this study

Summary

The Rheumatoid Arthritis DMARD Intervention and Utilization Study (RADIUS 1) is designed to systematically collect and document use patterns, effectiveness, and safety of DMARD treatments currently used in the management of rheumatoid arthritis (RA). It is anticipated that study data may help improve the quality of information upon which clinical decisions are based.

Conditions

Interventions

DRUG

DMARD

All subjects were required to initiate, add or change DMARD therapy at study entry.

Sponsors & Collaborators

  • Immunex Corporation

    collaborator INDUSTRY

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Amgen

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2007-12-31
Completion
2008-10-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116714 on ClinicalTrials.gov